MarketCap
Facebook
X
Telegram
Nuvation Bio Cost of Revenue | NUVB
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Nuvation Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 7.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.08 M | 7.08 M | 7.08 M |
Quarterly Cost of Revenue Nuvation Bio
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 3.35 M | 2.58 M | 2.09 M | - | 1.52 M | 1.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 M | 1.35 M | 2.18 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Protalix BioTherapeutics
PLX
|
27 M | $ 2.49 | -2.35 % | $ 196 M |  Israel |
 |
uniQure N.V.
QURE
|
1.69 M | $ 21.65 | -3.5 % | $ 1.24 B |  Niderland |
 |
Incyte Corporation
INCY
|
372 M | $ 113.3 | -2.08 % | $ 22.1 B |  USA |
 |
Mesoblast Limited
MESO
|
5.13 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
1.65 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
43.6 M | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
5.42 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
364 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
49 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Evogene Ltd.
EVGN
|
4.09 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
Fortress Biotech
FBIO
|
20.9 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
1.26 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
135 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Sanofi
SNY
|
13 B | $ 41.77 | 0.41 % | $ 51 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
36.7 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
199 K | - | -3.76 % | $ 3.47 M | USA |
 |
Heron Therapeutics
HRTX
|
41.3 M | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
32.7 M | $ 17.02 | 0.98 % | $ 2.29 B |  Canada |
 |
iBio
IBIO
|
216 K | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
16.2 M | $ 10.21 | -0.37 % | $ 92.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
1.08 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
InMed Pharmaceuticals
INM
|
3.24 M | $ 1.57 | 9.03 % | $ 6.54 M | Canada |
 |
Iovance Biotherapeutics
IOVA
|
173 M | $ 13.78 | -2.24 % | $ 4.92 M | USA |
 |
Theratechnologies
THTX
|
18.4 M | - | - | $ 83.9 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
70 K | - | -15.15 % | $ 60.3 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
2.03 M | - | - | $ 521 M | USA |
 |
Axon Enterprise
AXON
|
1.12 B | $ 424.81 | 1.06 % | $ 33.2 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
49.4 M | - | - | $ 2.02 B | USA |